Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types. 

Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. 

Members of the Caribou herd open their minds to new ideas and welcome diverse perspectives. We proudly assert that teams do their best work when their members are personally engaged, their ideas are taken seriously, their contributions are recognized, and their needs are met. 

Interested in joining our team? Please check out our jobs at
https://cariboubio.bamboohr.com/jobs/

Intellia Therapeutics

Janus Henderson Investors

LifeSci Venture Partners

Maverick Ventures

Heritage Group

Ridgeback Capital

Farallon Capital Management

AbbVie Biotech Ventures

Adage Capital Management

Avego Bioscience Capital

Avidity Partners

Caribou Biosciences

Join our VP, clinical development Socorro Portella, MD, and director of clinical research Ashley Hammad, AG-CNS, tomorrow at the #CRISPR 2.0 workshop, A 101 in First-in-Human CRISPR Trials taking place at 1:00pm ET tomorrow.

Kevin Liao, associate director, supply chain, will lead a workshop at the Donor Selection and Cell Source Summit. Join him on Tuesday, Nov. 28 at 1 pm ET.

The Caribou team will be presenting at the 4th Annual #CRISPR 2.0 Conference next week in Boston! Socorro Portella, MD, and Ashley Hammad, RN, will lead a workshop on Tuesday, Nov. 28 at 1 pm ET and Enrique Zudaire, PhD, will present on Thursday, Nov. 30 at 11:45 am ET. #CRISPR #CARTcell

Members of the Caribou team enjoyed an incredible night celebrating the accomplishments of Paul Donohoue, associate director of platform discovery and co-inventor of Caribou’s chRDNA technology, and the other nine esteemed winners of the 2023 Biocom California Catalyst Awards. Join us, once again, in congratulating Paul on this very well-deserved recognition of his innovation and scientific advancement in #CRISPR genome-editing technologies.  

Want to learn more about one of Paul's inventions? Check it out here: https://lnkd.in/gbEsNexH

Tune in for our company presentation by President and CEO Rachel Haurwitz, PhD, at the Jefferies London Healthcare Conference. A link to the webcast is on the investor section of our website: https://lnkd.in/gjSwyTzc

Caribou would be nothing without the incredible people who make up #theHerd. We are starting a new series to highlight Caribou’s leaders and explore their team’s impact, why they joined Caribou, and what drives them to develop allogeneic CAR-T cell therapies. We start the series with Enrique Zudaire, PhD. Watch the video to learn more about Kike!

Ahead of Veterans Day, we’d like to extend our gratitude to American veterans, especially those who are part of #TheHerd. Thank you for your service. #VeteransDay

This year, we have advanced our programs to build value across the pipeline and position Caribou as a leader in the allogeneic CAR-T cell therapy space. Learn more about our progress in our Q3 2023 financial results here: https://lnkd.in/gcXfDtbf #CRISPR #CARTcelltherapy

We are excited to announce the appointment of Jagannath Sundar, MD, to our scientific advisory board. We welcome Dr. Jagannath and his insights as a renowned expert in the treatment of #multiplemyeloma.
https://lnkd.in/eM47dKkA

Don’t miss Caribou Biosciences at upcoming investor conferences—tune in to available webcasts here: https://lnkd.in/gjSwyTzc

Domain Not Resolving

DNSSEC

U.S. Server Location

jQuery CDN

UNPKG

Vimeo

Hetzner

Mobile Optimized

New Relic

AddThis

Jeffrey Long-McGie

David L. Johnson

Philip Austin

Rodolphe Barrangou

Santhosh Palani

Martin Jinek

Co-founder

Jennifer Doudna

Co-Founder

James Berger

Rachel E. Haurwitz

Co-founder, President & CEO

Steven Kanner

Chief Scientific Officer

Barbara McClung

Chief Legal Officer, Corporate Secretary

Meghdad Rahdar

Director

Tina Albertson

Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.

San Francisco Bay Area Companies With More Than 10 Employees (Top 10K)

Health Care Companies With Less Than $500M in Revenue (Top 10K)

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

California Companies With More Than $1M in Revenue (Top 10K)

Caribou Biosciences is an operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling the development of therapeutics for agricultural biotechnology, industrial biotechnology, and basic and applied biological research.

Post-IPO Equity - Caribou Biosciences

Pfizer

PFM Health Sciences

Series C - Caribou Biosciences

Venture Round - Caribou Biosciences

Anterra Capital

Series B - Caribou Biosciences

Genoa Ventures

Series A - Caribou Biosciences

Grant - Caribou Biosciences

National Science Foundation

Berkeley

California

United States

North America

Caribou Biosciences to Participate in Upcoming Investor Conferences

A method of capturing crispr endonuclease cleavage products

Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU

Caribou to slash preclinical allogeneic CAR-NK work, lay off 12% of staff

Is Caribou Biosciences (NASDAQ:CRBU) In A Good Position To Deliver On Growth Plans?

Caribou Bioscience GAAP EPS of -$0.46 misses by $0.05, revenue of $2.43M beats by $0.01M

A genome-editing technology that combines RNA and DNA to enhance precision and reduce off-target effects in CRISPR applications.

Allogeneic CAR-T cell therapies developed from healthy donor cells, designed to be readily available for treating hematologic malignancies and autoimmune diseases.

An allogeneic anti-CD19 CAR-T cell therapy with checkpoint disruption to target B cell non-Hodgkin lymphoma and reduce T cell exhaustion.

An allogeneic anti-BCMA CAR-T cell therapy with immune cloaking to target multiple myeloma and prevent immune rejection.

An allogeneic anti-CLL-1 CAR-T cell therapy with both checkpoint disruption and immune cloaking to target acute myeloid leukemia.

South Korea

Asia

New Zealand

Oceania

Canada

India

HTML5

jQuery

Bootstrap

Adobe Fonts

Amazon Route 53

Google Tag Manager

GoDaddy

Microsoft Outlook

Apache Server

Editas Medicine is a leading genome editing company that focuses on developing transformative genomic medicines to treat a range of serious diseases.

Editas Medicine

Intellia Therapeutics is a biotechnology company focused on developing CRISPR/Cas9-based therapies for genetic diseases.

CRISPR Therapeutics is a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases.

CRISPR Therapeutics

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases. The company's patented chRDNA technology enables precision genome editing and the development of off-the-shelf CAR-T and CAR-NK cell therapies from healthy donor cells.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

news impact assignment basic	general	Mar 8, 2024 9:09 AM	b9fd3cb9
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 9:09 AM	f0388058
company summary	general
signals	general	Mar 8, 2024 9:09 AM	79221412
crunchbase trigger	general	Nov 22, 2024 7:44 AM	736d392e
crunchbase profile	general	Nov 22, 2024 9:31 AM	8ac4d1b0
li profile	general	Mar 8, 2024 9:09 AM	5c3bde6c
translate crunchbase fundingrounds	general	Nov 22, 2024 1:53 PM	0d082fe2
peers	general	Mar 8, 2024 9:09 AM	d2935fd6
news basic	general	Mar 8, 2024 9:09 AM	cff0a137
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CARIBOUBIO

Caribou Biosciences

Last Close

1.98

22/11 21:00

Market Cap

153.54M

Beta: -

Volume Today

989.16K

Avg: -